Restricted accessResearch articleFirst published online 2010-02
Differential Effects of P-Class Versus Other CpG Oligodeoxynucleotide Classes on the Impaired Innate Immunity of Plasmacytoid Dendritic Cells in HIV Type 1 Infection
Human plasmacytoid dendritic cells (PDC) are the major producers of type I interferons (IFN) after stimulation with CpG oligodeoxynucleotides (ODN). HIV-1-infected patients show a deficit in PDC numbers and function with progression of disease. CpG ODN appear to be attractive therapeutics to support the impaired innate immunity in HIV-1 infection. PDC counts, phenotype, and function were analyzed in 23 HIV-infected untreated individuals and 16 controls. Markers for migration (CCR7), activation (CD80), maturation (CD83), and endocytosis (BDCA2) were evaluated at baseline and 20 h after in vitro stimulation with class A, B, C, and P ODN. PDC counts and the expression of BDCA2 on these cells were significantly lower in HIV-1-infected subjects compared to controls (both p < 0.001). After stimulation with CpG ODN, CD80 and CD83 were upregulated to a similar extent in patients and controls, whereas CCR7 was upregulated more efficiently by CpG-P and CpG-C than CpG-A in HIV-1-infected individuals compared to controls. The IFN-α induction significantly differed for the CpG ODN classes (A > P > C > B) in patients and controls (p < 0.05). Functional PDC deficits in IFN-α and TNF-α induction were particularly evident in subjects with less than 500 CD4+ cells/μl. CpG-P ODNs not only induced remarkable IFN-α production in patient PBMCs, but also significantly upregulated the antibacterial and antiviral CXC chemokine IP-10. In conclusion, PDC counts, phenotype, and function are significantly impaired in HIV-1-infected subjects. Optimized P-class ODN may be effective in reversing this innate immune defect, which should be further evaluated in vivo.
Get full access to this article
View all access options for this article.
References
1.
CellaM, JarrossayD, FacchettiFet al.Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nature Med, 1999; 5,8:919–923.
2.
SiegalFP, KadowakiN, ShodellMet al.The nature of the principal type 1 interferon-producing cells in human blood. Science, 1999; 284,5421:1835–1837.
3.
BeutlerB. Innate immunity: An overview. Mol Immunol, 2004; 40,12:845–859.
4.
KadowakiN, HoS, AntonenkoSet al.Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med, 2001; 194,6:863–869.
Fitzgerald-BocarslyP, FengD. The role of type I interferon production by dendritic cells in host defense. Biochimie, 2007; 89:843–855.
7.
CellaM, FacchettiF, LanzavecchiaA, ColonnaM. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol, 2000; 1,4:305–310.
8.
KadowakiN, AntonenkoS, LauJYN, LiuYJ. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med, 2000; 192,2:219–225.
9.
RissoanMC, SoumelisV, KadowakiNet al.Reciprocal control of T helper cell and dendritic cell differentiation. Science, 1999; 283,5405:1183–1186.
10.
AlmeidaM, CorderoM, AlmeidaJ, OrfaoA. Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection. AIDS, 2005; 19,3:261–271.
11.
ChehimiJ, CampbellDE, AzzoniLet al.Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol, 2002; 168,9:4796–4801.
12.
DonaghyH, PozniakA, GazzardBet al.Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood, 2001; 98,8:2574–2576.
13.
FeldmanS, SteinD, AmruteSet al.Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. Clin Immunol, 2001; 101,2:201–210.
14.
FinkeJS, ShodellM, ShahK, SiegalFP, SteinmanRM. Dendritic cell numbers in the blood of HIV-1 infected patients before and after changes in antiretroviral therapy. J Clin Immunol, 2004; 24,6:647–652.
15.
KillianMS, NorrisPJ, RawalBDet al.The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response. AIDS Res Hum Retroviruses, 2006; 22,7:640–647.
16.
PacanowskiJ, KahiS, BailletMet al.Reduced blood CD123(+) (lymphoid) and CD11c(+) (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood, 2001; 98,10:3016–3021.
SchmidtB, FujimuraSH, MartinJN, LevyJA. Variations in plasmacytoid dendritic cell (PDC) and myeloid dendritic cell (MDC) levels in HIV-infected subjects on and off antiretroviral therapy. J Clin Immunol, 2006; 26,1:55–64.
19.
SoumelisV, ScottI, GheyasFet al.Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood, 2001; 98,4:906–912.
20.
SiegalFP, Fitzgerald-BocarslyP, HollandBK, ShodellM. Interferon-alpha generation and immune reconstitution during antiretroviral therapy for human immunodeficiency virus infection. AIDS, 2001; 15,13:1603–1612.
21.
BarronMA, BlyveisN, PalmerBE, MaWhinneyS, WilsonCC. Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals. J Infect Dis, 2003; 187,1:26–37.
22.
DonaghyH, GazzardB, GotchF, PattersonS. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood, 2003; 101,11:4505–4511.
23.
DesaiS, ChaparroA, LiuHet al.Impaired CCR7 expression on plasmacytoid dendritic cells of HIV-infected children and adolescents with immunologic and virologic failure. J Acquir Immune Defic Syndr, 2007; 45,5:501–507.
24.
HartmannG, WeinerGJ, KriegAM. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA, 1999; 96,16:9305–9310.
25.
KriegAM, YiAK, MatsonSet al.CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 1995; 374,6522:546–549.
26.
GurselM, VerthelyiD, GurselI, IshiiKJ, KlinmanDM. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol, 2002; 71,5:813–820.
27.
HartmannG, WeeratnaRD, BallasZKet al.Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol, 2000; 164,3:1617–1624.
28.
SivoriS, CarlomagnoS, MorettaL, MorettaA. Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells. Eur J Immunol, 2006; 36,4:961–967.
29.
VerthelyiD, IshiiKJ, GurselM, TakeshitaF, KlinmanDM. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol, 2001; 166,4:2372–2377.
30.
MarshallJD, FearonK, AbbateCet al.Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol, 2003; 73,6:781–792.
31.
VollmerJ, WeeratnaR, PayettePet al.Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol, 2004; 34,1:251–262.
32.
SamulowitzU, WeberM, WeeratnaRet al.A novel class of immune stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. Oligonucleotides(in press).
33.
VerthelyiD, WangVW, LifsonJD, KlinmanDM. CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. AIDS, 2004; 18,7:1003–1008.
34.
CooperCL, DavisHL, AngelJBet al.CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS, 2005; 19,14:1473–1479.
35.
MartinsonJA, TenorioAR, MontoyaCJet al.Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology, 2007; 120,4:526–535.
CooperCL, AhluwaliaNK, EflerSMet al.Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers. J Immune Based Ther Vaccines, 2008; 6:3.
DzionekA, SohmaY, NagafuneJet al.BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med, 2001; 194,12:1823–1834.
44.
TiltonJC, ManionMM, LuskinMRet al.Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro. J Virol, 2008; 82,8:3997–4006.
45.
HondaK, OhbaY, YanaiHet al.Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature, 2005; 434,7036:1035–1040.
46.
HerbeuvalJP, ShearerGM. HIV-1 immunopathogenesis: How good interferon turns bad. Clin Immunol, 2007; 123,2:121–128.
47.
McHutchisonJG, BaconBR, GordonSCet al.Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology, 2007; 46,5:1341–1349.
